Elliot Wilbur

Stock Analyst at Raymond James

(2.07)
# 1335
Out of 5,218 analysts
96
Total ratings
43.33%
Success rate
33.37%
Average return
22 Stocks
Name Action Price Target Current % Upside Ratings Updated
ADMA Biologics
Maintains: Strong Buy
18 25
18.58 34.55% 7 Nov 8, 2024
ANI Pharmaceuticals
Maintains: Outperform
81 83
56.38 47.22% 12 Sep 18, 2024
Sol-Gel Technologies
Downgrades: Outperform
6 4
0.5 700% 8 Aug 19, 2024
Organon
Initiates Coverage On: Outperform
33
15.32 115.4% 1 Mar 16, 2023
Perrigo
Maintains: Outperform
42 43
27.42 56.82% 6 Mar 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
21 16
n/a n/a 5 Oct 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Outperform
450 120
2.61 4497.7% 3 Sep 6, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 6 May 23, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 10
n/a n/a 4 May 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 5 Apr 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 3 Mar 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 4 Oct 28, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 6 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 4 Jul 16, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
n/a
n/a n/a 1 Jan 10, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Nov 26, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
181 166
n/a n/a 5 May 9, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Market Perform
n/a
n/a n/a 2 Jan 17, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
172 0
n/a n/a 3 Aug 21, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
58 0
n/a n/a 3 Aug 8, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
18 0
n/a n/a 3 Nov 9, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 3 Mar 9, 2017